Predict Arrhythmia Risk Using Intelligent Software (PARIS)
Artificial Intelligence-based Prediction and Detection of Critical Arrhythmias in Acute Cardiac Illness.
Cardiac arrhythmias frequently occur in patients admitted to the Coronary Care Unit (CCU). The majority of these patients are treated for an acute myocardial infarction, which carries an increased risk of life-threatening arrhythmias such as ventricular tachycardia (VT) or ventricular fibrillation (VF). This risk is one of the reasons these patients are monitored for 48 hours after a myocardial infarction, in accordance with the guidelines of the European Society of Cardiology (ESC) for acute coronary syndrome. Other arrhythmias, such as asystole, atrial fibrillation, or atrioventricular block, also occur in CCU patients. These arrhythmias are recorded on the electrocardiogram (ECG) monitor in the CCU and trigger an alarm for healthcare staff. However, in order to apply this alarming with sufficient sensitivity, many false positive alarms are also produced, which increases the workload for nurses (alarm fatigue) and undermines patient well-being.
This study will investigate whether Artificial Intelligence (AI) models, using continuous ECG data, can help improve the prediction of patients at risk of a life-threatening cardiac arrhythmia. Firstly, this study will aim to predict patients at risk of VT/VF in both the short term (30 minutes) and long term (1 day) in patients under continuous telemetric monitoring. This prediction facilitates timely intervention by the team in the short term, and in the long term, the safe transfer of a patient to a lower-complexity ward or earlier safe discharge of a patient. Secondly, this study will aim for improved detection to reduce the number of false negative alarms and thereby reduce alarm fatigue.
The performance of these AI models can be evaluated through this retrospective observational study. Patients aged 18 years or older who have been admitted with acute cardiac disease will be included. The primary objective of this study will be to evaluate the performance of AI models that detect and predict critical arrhythmias in the short and long term, using ECG data obtained via the monitoring system.
調査の概要
状態
詳細な説明
Primary objective:
Assessment of the performances of AI models in identifying patients at risk of sustained VT and VF from bedside monitor ECG in different timeframes:
- 30-minute prediction model
- 1-day prediction model
Secondary objectives:
• Assessment of potential healthcare savings if the AI model in would be used in clinical practice, such as CCU length-of-stay (CCU-LOS), hospital length-of-stay and associated costs
Exploratory objectives:
- Real time and continuous detection of events for alarming
- Prediction of other types of arrhythmias (e.g., Atrial fibrillation (AF), atrioventricular block, severe brady-arrhythmia) using in hospital ECG monitoring.
- Identification of clinical risk factors for sustained VT and/or VF
- Exploration of development and assessment of new AI models using new (clinical) input
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Maud E Kortman, M.D.
- 電話番号:040 239 9111
- メール:maud.kortman@catharinaziekenhuis.nl
研究連絡先のバックアップ
- 名前:Luuk C Otterspoor, Dr. M.D.
- メール:luuk.otterspoor@catharinaziekenhuis.nl
研究場所
-
-
North Brabant
-
Eindhoven、North Brabant、オランダ、5623 EJ
- 募集
- Catharina Hospital Eindhoven
-
コンタクト:
- Maud E Kortman, M.D.
- 電話番号:040 239 9111
- メール:maud.kortman@catharinaziekenhuis.nl
-
主任研究者:
- Luuk C Otterspoor, Dr. M.D.
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion criteria:
- Patients admitted from 1/1/2023*
- Patients aged 18 years or older
- Admitted for acute cardiac illness or after elective cardiac procedures
- Who are on ECG monitoring in the CCU, ICU or ward
Patients for whom continuous waveform ECG data have been routinely stored.
- Continuous waveform ECG data has been routinely stored in the CZE since 1/1/2023 on the ICU, since 1/12/2025 on the CCU and on the ward it has yet to be implemented. As our project utilizes this continuous ECG data, it will only include patients for whom this data is available.
Exclusion Criteria:
- Patients who expressed their preference for not having their data used for scientific research or to improve quality of care in the opt-out program of the CZE.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
Adult patients admitted for acute cardiac illness/elective cardiac procedures on ECG monitoring
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Occurrence of sustained ventricular tachycardia or ventricular fibrillation
時間枠:During admission
|
The primary outcome of the study is the occurrence of sustained ventricular tachycardia (VT) (monomorphic and polymorphic with a heartrate > 100 bpm and duration > 30 seconds or with hemodynamic compromise such as fainting or need for resuscitation) or ventricular fibrillation.
(Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
During admission
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Secondary outcome measure
時間枠:During admission
|
- A 'textbook' outcome (no adverse events) (Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
During admission
|
|
Secondary Outcome Measure
時間枠:during admission
|
- In-hospital onset and offset of cardiac arrhythmias (e.g.
atrial fibrillation, atrio-ventricular block or severe tachy- or bradyarrhythmia, non-sustained VT).
(Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
during admission
|
|
Secondary outcome measure
時間枠:During admission
|
- In hospital death/cardiovascular in-hospital death (include cause if available) (Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
During admission
|
|
Secondary outcome measure
時間枠:During admission
|
- Pulseless electrical activity (PEA) and asystole (Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
During admission
|
|
Performance of AI prediction model
時間枠:During admission
|
Discrimination of AI prediction model expressed with Area Under the Receiver Operating Characteristic curve (AUROC), Area Under the Precision-Recall Curve (AUPRC), sensitivity, specificity, (Positive Predictive Value) PPV and (Negative Predictive Value) NPV
|
During admission
|
協力者と研究者
捜査官
- 主任研究者:Luuk C Otterspoor, Dr. M.D.、Catharina Ziekenhuis Eindhoven
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- nWMO-2025.186
- project code 24PPS046 (その他の助成金/資金番号:National collaboration: Holland High Tech, Eindhoven University of Technology, Catharina Hospital Eindhoven, Philips)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。